Medacta announces first revision surgeries in the US using the unique-on-the-market and innovative MyKnee R patient-specific solution 21.09.2022, 19:00 Uhr von EQS News Jetzt kommentieren: 0

Werte zum Artikel
Name Aktuell Diff. Börse
Medacta Group 171,70 EUR -1,04 % Baader Bank

Medacta Group SA / Key word(s): Market Launch
Medacta announces first revision surgeries in the US using the unique-on-the-market and innovative MyKnee R patient-specific solution

21.09.2022 / 19:00 CET/CEST


 

Media release


Medacta announces first revision surgeries in the US using the unique-on-the-market and innovative MyKnee R patient-specific solution

CASTEL SAN PIETRO, Switzerland, September 21, 2022 – Medacta announced today the completion of the first revision surgeries in the US using MyKnee® R, the game-changing technology for streamlining and guiding total knee revision surgeries where even highly experienced surgeons can face complex and time-consuming procedures.

One of the most challenging aspects of revision knee arthroplasty is the detection of anatomic landmarks for proper positioning of the new implant. I found the MyKnee R preoperative planning capability incredibly useful in eliminating many of the surprises that we encounter intraoperatively,” says Jay Patel, D.O., at Atlanta Orthopaedic Institute, Atlanta, GA, USA.

MyKnee R provides personalized 3D interactive preoperative planning and a set of 3D-printed guide blocks. These guides are placed directly on the existing primary implant in situ to guide the placement of new implants from Medacta’s comprehensive knee portfolio, ranging from a lower level of constraint (GMK® Sphere and GMK® Primary) to semi- and fully constrained solutions (GMK® Revision and GMK® Hinge). These implants are part of a synergistic system that allows for intraoperative flexibility and are available with the SensiTiN™ ceramic-like coating, an option designed for reduced metal ion release.

With MyKnee R, it is also possible to plan the position of the GMK System’s revision options (i.e., 3D Metal cones, extension stems, offsets, and augments), addressing the high variation in knee revision scenarios with maximized versatility.

“Revision TKA can present many intraoperative surgical challenges, primarily due to substantial bone loss at the distal femur and/or proximal tibia. The unique ability to preoperatively plan and, most importantly, visualize the positioning, orientation, and sizing of revision constructs with MyKnee R has been extremely helpful in anticipating, evaluating, and treating some of these intraoperative hurdles,” says Kris J. Alden, M.D., Ph.D., at the Illinois Bone & Joint Institute, USA.

MyKnee R is part of the MySolutions Personalized Ecosystem, Medacta’s advanced network of digital solutions designed to improve patient outcomes and healthcare efficiency. Together with a comprehensive implant portfolio, from unicompartmental to hinged systems, MySolutions empowers Medacta’s holistic approach to personalized medicine, bringing value at every step throughout the entire patient journey.

MyKnee R is also supported by the comprehensive, tailored educational offering provided by the M.O.R.E. Institute. With an international network of expert surgeons, the M.O.R.E. Institute is at the forefront of education on total knee replacement techniques and products with personalized high-level educational pathways. With Medacta the surgeon is never alone.

Discover more about MyKnee R and Medacta’s knee portfolio.

 

 

 

Contact

Medacta International SA

Gianluca Olgiati

Senior Director Global Marketing

Phone: +41 91 696 60 60

media@medacta.ch

 

About Medacta

Medacta is an international company specializing in the design, production, and distribution of innovative orthopaedic products, as well as in the development of accompanying surgical techniques. Established in 1999 in Switzerland, Medacta is active in joint replacement, spine surgery, and sports medicine. Medacta is committed to improving the care and well-being of patients and maintains a strong focus on healthcare sustainability. Medacta's innovation, forged by close collaboration with surgeon experts globally, began with minimally invasive surgical techniques and has evolved into personalized solutions for every patient. Through the M.O.R.E. Institute, Medacta supports surgeons with a comprehensive and tailored program dedicated to the advancement of medical education. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 40 countries.

https://www.medacta.com

 

 


Additional features:

File: Medacta announces first revision surgeries in the US using the unique-on-the-market and innovative MyKnee R


End of Media Release


Language: English
Company: Medacta Group SA
Strada Regina
6874 Castel San Pietro
Switzerland
Phone: +41 91 696 6060
E-mail: info@medacta.ch
Internet: www.medacta.com
ISIN: CH0468525222
Listed: SIX Swiss Exchange
EQS News ID: 1447661

 
End of News EQS News Service

1447661  21.09.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1447661&application_name=news&site_id=boersennews
Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer